SEC Form 4 · accession 0000899243-18-018026
Kezar Life Sciences, Inc. · KZR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Jun 25, 2018
Accepted (ET)
Jun 25, 2018 · 9:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645666
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Jun 25, 2018 | C | 1,121,384 | — | A | 1,121,384 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Redeemable Convertible Preferred StockF2,F3,F1 | — | Jun 25, 2018 | C | 1,121,384 | D | — | — | Common Stock | 1,121,384 | 0 | D |
Explanation of responses
- F1As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will be automatically converted into one share of the Issuer's common stock.
- F2These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx.
- F3Upon the closing of the Issuer's initial public offering on the date hereof, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock.